63. 特発性血小板減少性紫斑病 Idiopathic thrombocytopenic purpura Clinical trials / Disease details
臨床試験数 : 391 / 薬物数 : 235 - (DrugBank : 50) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 139
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2000039630 | 2021-01-01 | 2020-11-03 | Phase II clinical trial of the superiority of montelukastine in combination with TPO-MPL agonists for the treament of primary immune thrombocytopenia | Phase II clinical trial of the superiority of montelukastine in combination with TPO-MPL agonists for the treament of primary immune thrombocytopenia | Primary immune thrombocytopenia | experimental group:Montelukast sodium 10mg/day; rhTPO 15000 units;control group:rhTPO 15000 units; | Department of Hematology, Second Medical Center, Chinese PLA General Hospital | NULL | Recruiting | 14 | 80 | Both | experimental group:51;control group:51; | Phase 2 | China |